SeekingAlpha•2026-04-22
IDEXX Laboratories Vs. Zoetis: A Pre-Earnings ComparisonELAN — Elanco Animal Health Inc
NYSE · Pharmaceuticals · Pharmaceuticals
$22.61+6.20%Market cap11.47B
- Latest Close
- $22.61
- 30-Day Move
- +6.2%
- Market Cap
- $11.5B
- Shares Outstanding
- 497,170,000
- P/B Ratio
- 1.72
- ROE
- -3.5%
Analyst consensus: Buy · 22 analysts
NYSE:ELANPharmaceuticals / PharmaceuticalsDelayed public snapshot
Elanco Animal Health Inc
A read-only Alphactor snapshot forElanco Animal Health Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$22.61
30-Day Move
+6.2%
Market Cap
$11.5B
Shares Outstanding
497,170,000
P/B Ratio
1.72
ROE
-3.5%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$22.61
+6.2%last 90 delayed daily bars
Market cap$11.5B
90D High
$27.72
90D Low
$20.96
Avg Volume
5,006,660
What stands out
Gross margin is running at 55.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -4.9%, useful for comparing ELAN against peers in Pharmaceuticals.
ELAN is up 6.2% over the last 30 trading days shown on this page.
Latest operating income is $252M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$21.32
Rule of 40
12.2%
Dark Pool Short %
47.5%
Fundamentals snapshot
Latest Close
$22.61
30-Day Move
+6.2%
Market Cap
$11.5B
Shares Outstanding
497,170,000
P/B Ratio
1.72
ROE
-3.5%
ROA
-1.7%
Gross Margin
55.0%
Operating Margin
-4.3%
Net Margin
-4.9%
Debt / Equity
0.61
Current Ratio
2.17
Latest Revenue
$4.7B
Financial statement snapshot
Revenue
$4.7B
Gross Profit
$2.6B
Operating Income
$252M
Net Income
$-232M
Gross Margin
5499.0%
Net Margin
-492.0%
Current Ratio
2.17
Debt / Equity
0.61
Valuation snapshot
Fair Value
$21.32
Upside / Downside
-5.7%
Signal
Fairly Valued
Implied Growth
17.7%
DCF
$2.20
EV/Rev
$40.43
Growth Assumption
2.2%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$284M
Valuation spread
Current Price
$22.61
Composite Fair Value
$21.32
DCF
$2.20
EV/Rev
$40.43
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
1.36
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
-2.41x
Rule of 40
12.2%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $4.4B | $384M | $-78M | $268M |
| 2023-12-31 | $4.4B | $326M | $-1.2B | $131M |
| 2024-12-31 | $4.4B | $251M | $338M | $394M |
| 2025-12-31 | $4.7B | $252M | $-232M | $284M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
SeekingAlpha•2026-04-20
Elanco Animal Health: Relying On Innovation To Drive GrowthYahoo•2026-04-16
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results AnnouncementFintel•2026-04-16
Citigroup Initiates Coverage of Elanco Animal Health (ELAN) with Buy RecommendationYahoo•2026-04-15
Is Elanco (ELAN) Using Mass-Market Collars to Quietly Redefine Its Companion Animal Strategy?After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$937,907.09
Sell Value
$0
Buys
4
Sells
0
Buy Value
$937,907.09
Sell Value
$0
Buy/Sell Ratio
4.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | Modi Rajeev A. | A | 62 | $23.68 |
| 2026-04-17 | VanHimbergen Robert M | A | 8 | $23.68 |
| 2026-04-17 | Simmons Jeffrey N | A | 119 | $23.68 |
| 2026-04-03 | Modi Rajeev A. | A | 65 | $22.82 |
| 2026-04-03 | VanHimbergen Robert M | A | 9 | $22.82 |
| 2026-04-03 | Simmons Jeffrey N | A | 124 | $22.82 |
| 2026-04-01 | de Brabander Ellen | F | 20,288 | $23.12 |
| 2026-04-01 | de Brabander Ellen | A | 40,985 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 53,122,900 | 0.11% | 2025-12-31 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 17,863,839 | 0.04% | 2025-12-31 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 16,049,892 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 15,650,083 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 11,275,348 | 0.02% | 2025-12-31 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 10,303,076 | 0.02% | 2025-12-31 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 9,002,605 | 0.02% | 2026-02-28 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 7,947,200 | 0.02% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2026-02-17
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$1.2B
-20.1%
Vanguard Group
Filed 2026-01-29
$1.1B
-1.1%
BlackRock
Filed 2024-05-10
$434M
--
Geode Capital Management
Filed 2026-02-09
$213M
+7.3%
Citadel Advisors
Filed 2025-08-14
$196M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.27
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.